Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
ConclusionThe prevalence of CVD in patients with type 2 diabetes in clinical practice in Sweden was 28.3% during the study period, and it was 11.5% in the patients starting empagliflozin treatment. Patients of the latter cohort were, however, younger, more obese, and more likely to have unsatisfactory glycemic control, requiring additional treatment. Overall, a large proportion of type 2 diabetes patients should be considered at high cardiovascular risk.FundingBoehringer Ingelheim AB, Sweden.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Congestive Heart Failure | Coronary Heart Disease | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Empagliflozin | Endocrinology | Heart | Heart Disease | Heart Failure | Insulin | Jardiance | Obesity | Peripheral Vascular Disease (PVD) | Stroke | Study | Sweden Health